# A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

> **NCT04896112** · PHASE1 · WITHDRAWN · sponsor: **Lynk Pharmaceuticals Co., Ltd**

## Conditions studied

- Acute Myeloid Leukemia
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Polycythemia Vera

## Interventions

- **DRUG:** LNK01002

## Key facts

- **NCT ID:** NCT04896112
- **Lead sponsor:** Lynk Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04-08
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-10-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04896112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04896112, "A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04896112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*